This extreme degree of lineage plasticity is also seen in patients with MLL-AF4 infant leukaemia, where lineage switching can occur, particularly, upon CD19-targeted therapy (Park et al., 2011; Rayes et al., 2016; Wölfl et al., 2018). This evidence concerns the gene AFF1 and leukemia.